Alcohol Use Disorder: Pharmacotherapy and Recovery
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Alcohol Use Disorder: Pharmacotherapy and Recovery
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
On-Demand Session
Overview
This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines new research on Alcohol Use Disorder (AUD) treatment, including findings from a cutting-edge alcohol registry, evidence outlining the role of the endocrine system in addiction, and advances in the use of computational modeling and biomarkers to advance personalized medicine for AUD.
Alcohol Use Disorder (AUD) is a heterogeneous disorder characterized by individual variation in clinical features, neurocognitive functioning, molecular pathways, and neural circuits making it challenging to treat. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course examines new research on AUD treatment, including findings from a cutting-edge alcohol registry, evidence outlining the role of the endocrine system in addiction, and advances in the use of computational modeling and biomarkers to advance personalized medicine for AUD. Following the session, a moderated panel discussion among the presenters answers audience questions.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Facilitating Recovery in the Context of Healthcare: Challenges and Opportunities
This presentation describes an approach to facilitating recovery across the spectrum of alcohol problems, from unhealthy use through severe alcohol use disorders, in the context of healthcare delivery. We discuss the development, implementation and uses of an innovative, cutting-edge Alcohol Registry, a collaboration between Kaiser Permanente Northern California and the National Institute on Alcohol Abuse and Alcoholism. The data in the Alcohol Registry provides critical diagnostic, alcohol consumption quantity and frequency, demographic and services utilization information for conducting epidemiologic, health services and implementation science research and informs quality improvement efforts across the continuum of care, from primary care to specialty addiction medicine. We discuss systemic challenges to enabling recovery from alcohol problems in healthcare settings, and describe ways to enhance systems? approach to alcohol treatment. - Gut-Brain Axis and Neuroendocrinology: Translation to Addiction Medicine
Endocrine signals from the periphery traditionally known to regulate homeostasis, fluid intake, appetite and food intake may play an important role in reward regulation as well as in development of alcohol and substance use disorders, therefore representing promising novel targets in medication development. Dr. Leggio on behalf of his research team and collaborators, will present recent translational preclinical and human data on systems related to the gut-brain axis and to neuroendocrine pathways. Examples include the ghrelin system, the glucagon-like peptide-1 (GLP-1) system and the aldosterone / mineralocorticoid receptor (MR) system. This line of research supports additional efforts aimed to investigate whether these neuroendocrine pathways may represent novel potential targets for medication development for addictions. - Beyond Treating Acute Alcohol Withdrawal: New Medications to Address Post-Withdrawal Relapse and Recovery
Despite several approved medications to treat Alcohol Use Disorder (AUD), there are high relapse and treatment failure rates in AUD. Clinical presentation of treatment entering individuals with AUD indicates significant heterogeneity, with severity of illness and varying levels of alcohol withdrawal symptoms and craving impacting treatment course and outcome. Data on effects of moderate to high severity AUD, stress biology and associated poor treatment response will also be shown. Finally, results from a 12-week randomized clinical trial of Prazosin will be presented to show that its efficacy is moderated by alcohol withdrawal symptoms. The findings will be discussed in the context of the need for valid clinical, neural and biological markers to address AUD heterogeneity to improve relapse risk and treatment outcome in AUD. - Leveraging Systems Pharmacology to Advance Precision Medicine for Treatment of Alcohol Use Disorder
There is an urgent need to personalize evidence-based treatments for alcohol use disorder (AUD). AUD is a heterogeneous disorder characterized by individual variation in clinical features, neurocognitive functioning, molecular pathways, and neural circuits. Advances will be presented in the use of computational modeling and biomarkers to advance personalized medicine for AUD by predicting likely responders to gabapentin, topiramate and other pharmacological treatments.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/1/2025
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Kathleen Page, MD (Moderator)
Associate Professor
Johns Hopkins University School of Medicine
Dr. Kathleen Page, MD, is an Associate Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her work focuses on improving access and quality of care to underserved communities. She co-founded Centro SOL to meet the health needs of Latino migrants through research, education, advocacy, and clinical care. She is the Medical Director of The Johns Hopkins Access Partnership which provides care to uninsured patients with financial need. Her research focuses on migrant health, health disparities and implementation science.
No Relevant Financial Disclosures
Stacy Sterling
MPH, MSW
Stacy Sterling, DrPH, MSW, MPH, is a senior research scientist with the Division of Research and co-directs its Center for Addiction and Mental Health Research. She is part of DOR's Drug and Alcohol Research Team (DART) and its Behavioral Health Research Initiative. Her research interests include developing systems for implementing evidence-based, integrated, behavioral health services into primary care, adolescent behavioral health prevention and early intervention, and alcohol and drug and mental health treatment outcomes and access. Dr. Sterling is a standing member of the National Institute of Alcohol Abuse and Addiction (NIAAA) Clinical, Treatment and Health Services Research study section. She is principal investigator of a study funded by the Conrad N. Hilton Foundation to develop predictive models for adolescent substance use problem development, and of studies funded by the Robert Wood Johnson Foundation and Center for Substance Abuse Treatment of adolescents in drug and alcohol treatment in Kaiser Permanente.
She is the Kaiser Permanente Principal Investigator of multiple studies including: a trial funded by the Hilton Foundation of single vs. multisession screening, brief intervention and referral to treatment (SBIRT) for adolescents and parents in pediatric primary care; a NIAAA adolescent SBIRT trial in pediatric primary care; an NIAAA trial of an innovative alcohol telemedicine consultation intervention, studies of the implementation and outcomes of large-sclae alcohol screening and brief intervention, and an NIAAA survey of pediatrician attitudes toward and practices of adolescent behavioral-health risk screening and intervention. Dr. Sterling was co-investigator of a cluster-randomized trial of SBIRT for unhealthy alcohol use in adult medicine in Kaiser Permanente Northern California. She co-authored a widely disseminated issue brief, "Reducing Risky Alcohol Use: What Health Care Systems Can Do" and has developed nationally disseminated educational materials including NIAAA's "The Healthcare Professional's Core Resource on Alcohol, 'Promote Practice Change: Take Manageable Steps Toward Better Care'." Dr. Sterling is the KPNC Training Director for an innovative hybrid National Institute of Mental Health T32 fellowship program and was recognized with DOR's Excellence in Mentoring Award.
She received her doctoral training at the University of North Carolina Gillings School of Global Public Health, and her master's degrees in Public Health and Social Welfare at the University of California, Berkeley.
No Relevant Financial Disclosures
Lorenzo Leggio
MD. PhD, MSc
Dr. Lorenzo Leggio serves as the Chief of the joint NIAAA/NIDA Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology. He received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and Board Certification in Internal Medicine. He received a Masters in Alcoholism from the University of Florence. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University. In 2010, he became Assistant Professor at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio's clinical research has been primarily focused on the treatment of alcoholism, with an emphasis on the role of feeding-related and GABAergic pathways; and on the medical consequences of alcoholism, with an emphasis on alcoholic liver disease. While at Brown, he received funding from NIH and various foundations. In 2012, Dr. Leggio joined NIAAA and NIDA as a joint Clinical Investigator and Section Chief. He is licensed and credentialed as Senior Attending Medical Staff at the NIH Clinical Center. Dr. Leggio also serves as the Associate Director for Clinical Research for the NIDA IRP Medication Development Program. Additionally, he is an Adjunct Associate Professor at the Brown University CAAS. Dr. Leggio's lab has pioneered clinical research on the role of neuroendocrine signaling in alcoholism. He has authored or co-authored over 100 peer-reviewed manuscripts and has served as reviewer for NIH study sections and other U.S. and international funding agencies. He has served as consultant for FDA advisory panels, and on the editorial boards of addiction-related journals. He has served as Chair (Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee. Among other awards, he received the 2008 ESBRA Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, and the 2016 RSA Early Career Investigator Award
No Relevant Financial Disclosures
.jpg "Speaker image")
Rajita Sinha, PhD
Foundations FUND Professor of Psychiatry, Neuroscience and Child Study
Yale University
Rajita Sinha, Ph.D. is the Foundations Fund Endowed Professor in Psychiatry, and Professor in Neuroscience and in Child Psychiatry at the Yale University School of Medicine. She is a licensed Clinical Psychologist and Clinical Neuroscientist, Chief of the Psychology Section in Psychiatry and Deputy Chair in Psychiatry for Psychology at the Yale University School of Medicine. She is the founding director of the Yale Interdisciplinary Stress Center that focuses on understanding the neural and psychobiological mechanisms underlying stress, trauma and alcohol and substance use behaviors as well as related conditions such as chronic pain, comfort food intake and obesity. She has developed novel drug craving, stress, pain and food reward provocation paradigms to understand mechanisms that drive these states and related pathologies. Her lab has also developed and tested novel pharmacological and behavioral interventions to address alcohol and substance use behavior change in the context of stress and trauma to decrease addiction relapse risk. She has received a number of awards for her work, including the recent Research Society on Alcoholism’s Distinguished Researcher Award in 2020, and also the James Tharp Award from the American Society of Addiction Medicine. Her research has been supported by a series of NIH funded research projects continuously for over 20 years. She has published over 325 scientific peer reviewed publications with an H-Index of 98 on Google Scholar and has been cited over 37,000 times. She currently serves on the National Scientific Advisory Council of NIDA and is on the National Institutes of Health’s (NIH) Expert Scientific Panel for the NIH Common Fund’s Science of Behavior Change program. She has also previously served as a member of the NIH/NIAAA Scientific Advisory Council. She has presented at numerous national and international conferences, and her work is widely cited.
Does Disclose: CT Pharma,LLC. Received a research grant to study medical cannabis for chronic pain.
Charles Marmar, MD
Lucius N. Littauer Professor and ChairDirector, Center for Precision Medicine in Alcohol Use Disorder and PTSD
Department of PsychiatryNYU Langone Health
Dr. Marmar is Lucius N. Littauer Professor and Chair, Department of Psychiatry, New York University Grossman School of Medicine, and Director of the NYU Langone Center for Precision Medicine in Alcohol Use Disorder and PTSD. Previously, Dr. Marmar was Professor & Vice Chair of the Department of Psychiatry at UCSF, & Associate Chief of Staff for Mental Health & Director of the PTSD Research Program at the San Francisco VA Medical Center. Dr. Marmar graduated from the University of Manitoba with a BSc in 1966 and an MD in 1970. He completed his residency in Psychiatry and Fellowship in Neuropsychopharmacology at the University of Toronto in 1976 and a Psychiatry Fellowship at the University of California, San Francisco in 1978.
Internationally renowned for his expertise in PTSD for over 35 years, his focus ranges from combat-related conditions in veterans, including Iraq and Afghanistan vets, to PTSD in refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level for both the VA and the National Institute of Mental Health (NIMH) and as counsel to the VA Medical Centers, fire departments, disaster response teams and police departments, including the NYPD. An award-winning teacher and researcher, Dr. Marmar is currently the principal investigator of numerous PTSD-related grants funded by NIAAA, the Department of Defense and private philanthropic organizations. He conducts studies in psychopharmacology, psychopathology, and psychobiology, quality of care, psychotherapy treatment and phenomenology of PTSD. He has served as president of the international societies for traumatic stress studies, and has published nearly 350 peer-reviewed manuscripts and chapters.
Does Disclose: Advisory Board for Otsuka Pharmaceuticals- Received honorarium for serving in advisory board for PTSD; Consultant for Roche Received honorarium for serving in advisory board for PTSD.
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
Locked